Navigation Links
GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
Date:1/3/2008

Compound 642444 and Compound 685698 advance in clinical development for the

treatment of asthma

LONDON, PHILADELPHIA and SAN FRANCISCO, Jan. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) today announced the start of large Phase 2b asthma dose-optimization studies with both the lead inhaled corticosteroid (ICS) GW685698 ('698) and the lead long-acting beta agonist (LABA) GW642444 ('444) assets in the 'Horizon' program to develop a next-generation combination product.

GSK began enrolling patients with mild to severe asthma in the '698 Phase 2b clinical program on 21st December 2007 and began enrolling patients with persistent asthma in the '444 Phase 2b clinical program on 29th December 2007. These clinical programs will determine the most effective doses to be taken into Phase 3 combination studies. The Phase 2b COPD program with '444 is also on schedule to commence in 1H 2008.

Darrell Baker, SVP GSK Respiratory Medicines Development Centre said, "The program is progressing well and we are delighted to have two very strong assets to progress into our large Phase 2b studies." He continued, "We have seen encouraging results in previous studies and have confidence in our ongoing program. Both asthma and COPD are serious, debilitating diseases where there remains a considerable unmet need. We believe through this program we will introduce a meaningful option for the treatment of patients with these conditions."

"We are very p
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
2. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
3. GlaxoSmithKline Accelerates Review of Exelixis XL880
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
8. FASgen Announces a New Discovery in Obesity Research
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces New Discovery for Treatment of Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... findings from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib ... antibody (a checkpoint inhibitor), suppression of tumor growth ... achieved when treating certain hematologic cancers and solid ...
(Date:2/27/2015)... Feb. 27, 2015 Securities lawyers at ... Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in ... Concerned SLXP investors are encouraged to contact attorney Hamilton ... The investigation focuses upon the shareholder value of the ... would receive only $158.00 per share in cash. At ...
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... When treating children for acute osteomyelitis--a bacterial ... to oral antibiotics is just as effective as continuing ... the oral drugs are more convenient for children and ... increased risk of complications from using central catheters, such ...
... Recombinant Factor IX (rFIX) Product for the Treatment of ... Inc., today announced the initiation of a Phase 1 ... IX (rFIX) product for control and prevention of hemorrhagic ... estimated that the market for therapies to treat this ...
Cached Medicine Technology:Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B 2
(Date:3/1/2015)... GA (PRWEB) March 01, 2015 ... Evelyn King and Carolyn Roddy to the professional staff ... of Compliance, graduated from The Ohio State University-Mortiz College ... 15 years of experience working with several Fortune 500 ... in the area of corporate benefits. Her experiences range ...
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3
... (HealthDay News) -- Patients who receive artificial joints made with ... loosen the new joint, according to a new study of ... Contrary to previous studies that blamed bacteria for the ... New Jersey reported that tiny titanium particles that flake off ...
... can be lulled to sleep by a factor released by ... in the Journal of Experimental Medicine ( www.jem.org ... patients after treatment, often as a result of metastases that ... at Southern Illinois University School of Medicine now show that ...
... may think about sex more often than women do, but a ... such as eating and sleep, more frequently than women do, as ... think about sex every seven seconds, which would amount to more ... study, the median number of young men,s thought about sex stood ...
... ,Heart function improved in obese people with type 2 diabetes ... says. Researchers measured body-mass index (BMI) and used MRI ... people (seven men and eight women) with type 2 diabetes ... diet. Pericardial fat collects around the heart and can ...
... in the developing world getting enough food to eat is ... A new issue of the international journal Energy Policy ... using the only energy source available to many people, woody ... of decision frameworks that are needed to guide policy development ...
... HILL Scientists at the ,University of North Carolina at ... that plays a central role in the formation of new ... and new blood vessel formation, or angiogenesis, is seriously impaired ... 16, 2011 in the journal Blood , was led ...
Cached Medicine News:Health News:Study debunks stereotype that men think about sex all day long 2Health News:Study debunks stereotype that men think about sex all day long 3Health News:Study debunks stereotype that men think about sex all day long 4Health News:Low-Cal Diet Cuts Fat Around Heart in Obese People: Study 2Health News:Saving millions of lives and protecting our climate through clean cooking options 2Health News:Saving millions of lives and protecting our climate through clean cooking options 3Health News:Cell molecule identified as central player in the formation of new blood vessels 2Health News:Cell molecule identified as central player in the formation of new blood vessels 3
2 mm wide curved tip. Round handle....
9 mm blade....
3 mm disposable bevel blades. Malleable shafts. Blades packaged 6 per package....
Straight 6 mm Lance blade. Can be placed in closed handle for protection. Angular handle. Length of sheath handle 105 mm, 4.2 inches....
Medicine Products: